CIK 0001253689 · Non-accelerated filer<br>Smaller reporting company
CRESCENT BIOPHARMA, INC.
Sign in to watch- Ticker
- CBIO
- Exchange
- Nasdaq
- Industry
- Pharmaceutical Preparations
- FY end
- Dec 31
- Incorporated
- Cayman Islands
- Entity type
- operating
- Phone
- 617-430-5595
- Business address
- 300 FIFTH AVENUE, WALTHAM, MA, 02451
- Former names
- GLYCOMIMETICS INC
- Open-market buys, last 90 days
- $0
- in 0 filings
- Open-market sales, last 90 days
- $285,501
- in 7 filings, $286K under 10b5-1 plans
Net −$285,501. Shares bought or sold at a price by officers, directors and 10% owners (Form 4 codes P and S). Grants, option exercises and tax withholding aren't counted.
Who's trading
90 days
- Brumm Joshua T −$160K Chief Executive Officer sold 3% of stake
- McNeill Jonathan −$77K President and COO sold 3% of stake
- Pinkas Jan −$12K Chief Scientific Officer sold 3% of stake
- Im Ellie Eunkyung −$11K Chief Medical Officer sold 3% of stake
- Bispham Barbara Harlin −$11K See Remarks sold 3% of stake
Reading 48 more Form 4s from the SEC; this list fills in as they're read.
| Date | Insider | Transaction | Shares | Price | Value | Owned after |
|---|---|---|---|---|---|---|
| 2022-01-21 | Hahn Brian M. SVP Finance, CFO | Grant or award · Employee Stock Option (right to buy) | +47,700 | 47,700 | ||
| 2022-01-21 | Semerjian Harout Chief Executive Officer | Grant or award · Employee Stock Option (right to buy) | +423,500 | 423,500 | ||
| 2021-11-16 | Andrews Patricia S Director | Purchase | +40,000 | $2.05 | $82K | 45,250 |
| 2021-05-18 | JUNIUS DANIEL M Director | Grant or award | +5,250 | 43,250 | ||
| 2021-05-18 | JUNIUS DANIEL M Director | Grant or award · Stock Option (right to buy) | +10,500 | 10,500 | ||
| 2021-05-18 | Jackson Scott Thomas Director | Grant or award | +5,250 | 5,250 | ||
| 2021-05-18 | Jackson Scott Thomas Director | Grant or award · Stock Option (right to buy) | +10,500 | 10,500 | ||
| 2021-05-18 | Andrews Patricia S Director | Grant or award | +5,250 | 5,250 | ||
| 2021-05-18 | Andrews Patricia S Director | Grant or award · Stock Option (right to buy) | +10,500 | 10,500 | ||
| 2021-05-18 | Goldberg Mark Alan Director | Grant or award | +5,250 | 5,250 | ||
| 2021-05-18 | Goldberg Mark Alan Director | Grant or award · Stock Option (right to buy) | +10,500 | 10,500 | ||
| 2021-05-18 | Koenig Scott Director | Grant or award | +5,250 | 5,250 | ||
| 2021-05-18 | Koenig Scott Director | Grant or award · Stock Option (right to buy) | +10,500 | 10,500 | ||
| 2021-05-18 | PEARSON TIMOTHY R Director | Grant or award | +5,250 | 5,250 | ||
| 2021-05-18 | PEARSON TIMOTHY R Director | Grant or award · Stock Option (right to buy) | +10,500 | 10,500 | ||
| 2021-01-20 | Girard Armand SVP, Chief Business Officer | Grant or award | +25,000 | 25,000 | ||
| 2021-01-20 | Girard Armand SVP, Chief Business Officer | Grant or award · Employee Stock Option (right to buy) | +50,000 | 50,000 | ||
| 2021-01-20 | Hahn Brian M. SVP Finance, CFO | Grant or award | +34,500 | 39,760 | ||
| 2021-01-20 | Hahn Brian M. SVP Finance, CFO | Grant or award · Employee Stock Option (right to buy) | +69,000 | 69,000 | ||
| 2021-01-20 | Thackray Helen M. SVP Clinical Development, CMO | Grant or award | +34,500 | 183,115 |
Page 9 of 16 · 305 trades